The timeline for FDA's complex innovative trial designs (CID) pilot program may require adjustment amid worries the eight-month timeline is too long to fit plans for advancing a product to market.
Dionne Price, acting deputy director of the Center for Drug Evaluation and Research's Office of Biostatistics, said sponsors should consider the timeline when applying to the CID program
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?